Sarepta Therapeutics, Inc.
SRPT
$20.49
$0.020.10%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 47.15% | 64.89% | 59.15% | 52.97% | 48.45% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 47.15% | 64.89% | 59.15% | 52.97% | 48.45% |
| Cost of Revenue | 91.05% | 102.53% | 78.73% | 9.33% | -0.15% |
| Gross Profit | -27.16% | 1.14% | 10.95% | 261.01% | 742.24% |
| SG&A Expenses | 0.30% | 8.72% | 13.32% | 15.77% | 11.70% |
| Depreciation & Amortization | -0.82% | 2.79% | 21.34% | 54.27% | 163.28% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 60.31% | 69.22% | 56.90% | 11.43% | 3.66% |
| Operating Income | -206.15% | -102.45% | -23.60% | 181.43% | 120.29% |
| Income Before Tax | -294.89% | -138.78% | -582.07% | 150.14% | 119.55% |
| Income Tax Expenses | 155.76% | 126.63% | 390.57% | 60.81% | -74.03% |
| Earnings from Continuing Operations | -322.84% | -222.54% | -1,570.01% | 143.89% | 117.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -322.84% | -222.54% | -1,570.01% | 143.89% | 117.64% |
| EBIT | -206.15% | -102.45% | -23.60% | 181.43% | 120.29% |
| EBITDA | -130.32% | -48.36% | -47.66% | 214.49% | 133.64% |
| EPS Basic | -311.23% | -221.51% | -1,881.02% | 140.26% | 116.50% |
| Normalized Basic EPS | -179.03% | -80.65% | -10.20% | 183.10% | 122.74% |
| EPS Diluted | -333.44% | -271.86% | -2,553.33% | 138.99% | 115.86% |
| Normalized Diluted EPS | -212.98% | -137.10% | -27.71% | 174.94% | 121.69% |
| Average Basic Shares Outstanding | 3.78% | 4.29% | 5.04% | 5.80% | 6.77% |
| Average Diluted Shares Outstanding | 4.26% | 7.45% | 8.44% | 12.18% | 11.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |